[{"id":"8fac6d48-bf25-4ede-b0bd-19869334e342","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472140","created_at":"2026-03-28T01:41:57.184Z","updated_at":"2026-03-28T01:41:57.184Z","phase":"Phase 2/3","brief_title":"PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT07472140","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"a7bc76a3-7767-4569-b28f-313c198056ba","acronym":"MAGNITUDE","url":"https://clinicaltrials.gov/study/NCT03748641","created_at":"2021-01-18T18:22:54.153Z","updated_at":"2025-02-25T13:52:43.687Z","phase":"Phase 3","brief_title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03748641 - MAGNITUDE","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HRD • BRCA","pipe":"","alterations":" ","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone • Akeega (abiraterone/niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 765","initiation":"Initiation: 01/25/2019","start_date":" 01/25/2019","primary_txt":" Primary completion: 10/08/2021","primary_completion_date":" 10/08/2021","study_txt":" Completion: 03/19/2027","study_completion_date":" 03/19/2027","last_update_posted":"2025-02-20"},{"id":"1823a066-42ab-41e9-bc3a-b338ae379009","acronym":"ORACLE","url":"https://clinicaltrials.gov/study/NCT06817174","created_at":"2025-02-25T14:12:17.340Z","updated_at":"2025-02-25T14:12:17.340Z","phase":"","brief_title":"Ovarian Cancer Radiomics Approach in CT Led Evaluation","source_id_and_acronym":"NCT06817174 - ORACLE","lead_sponsor":"Imperial College Healthcare NHS Trust","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 01/01/2032","primary_completion_date":" 01/01/2032","study_txt":" Completion: 01/01/2032","study_completion_date":" 01/01/2032","last_update_posted":"2025-02-19"},{"id":"2da5468a-79d4-4eeb-942f-5b05fa2fb4d8","acronym":"CERTIS1","url":"https://clinicaltrials.gov/study/NCT05417594","created_at":"2022-06-14T22:56:26.797Z","updated_at":"2025-02-25T14:08:54.388Z","phase":"Phase 1/2","brief_title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","source_id_and_acronym":"NCT05417594 - CERTIS1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan-dlnk) • AZD9574"],"overall_status":"Recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 06/24/2022","start_date":" 06/24/2022","primary_txt":" Primary completion: 08/28/2026","primary_completion_date":" 08/28/2026","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-19"},{"id":"ab61b8a8-7577-42c8-aace-25d2ec073ed7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05700721","created_at":"2023-01-26T15:02:55.768Z","updated_at":"2025-02-25T14:09:25.231Z","phase":"Phase 2","brief_title":"Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)","source_id_and_acronym":"NCT05700721","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 08/07/2025","primary_completion_date":" 08/07/2025","study_txt":" Completion: 08/07/2027","study_completion_date":" 08/07/2027","last_update_posted":"2025-02-17"},{"id":"cedde79c-686f-4afe-89d0-1fd3a8d96cf4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05200260","created_at":"2022-01-20T14:53:41.699Z","updated_at":"2025-02-25T14:38:18.943Z","phase":"Phase 2","brief_title":"Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer","source_id_and_acronym":"NCT05200260","lead_sponsor":"Shanghai Gynecologic Oncology Group","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • paclitaxel • docetaxel • Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-10"},{"id":"d42429d0-899b-4f9f-a9fd-c90fa6b9a50e","acronym":"NRG-GY027","url":"https://clinicaltrials.gov/study/NCT05276973","created_at":"2022-03-14T14:54:04.422Z","updated_at":"2025-02-25T16:38:53.900Z","phase":"Phase 1","brief_title":"Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05276973 - NRG-GY027","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1","pipe":" | ","alterations":" HRD","tags":["PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • ipatasertib (RG7440)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-07"},{"id":"8ba4b2c4-2d3e-460e-9a2f-77116f701fa8","acronym":"S1513","url":"https://clinicaltrials.gov/study/NCT02890355","created_at":"2021-01-18T14:11:10.280Z","updated_at":"2025-02-25T16:36:47.130Z","phase":"Phase 2","brief_title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02890355 - S1513","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CEACAM5","pipe":" | ","alterations":" HRD","tags":["BRCA1 • BRCA2 • HRD • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-06"},{"id":"70895122-f43e-478e-b06c-44c96910d6ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265872","created_at":"2021-04-20T09:53:17.764Z","updated_at":"2025-02-25T16:44:48.890Z","phase":"Phase 1","brief_title":"Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC","source_id_and_acronym":"NCT04265872","lead_sponsor":"Baylor Research Institute","biomarkers":" ER • HRD","pipe":" | ","alterations":" HRD • ER negative","tags":["ER • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-05"},{"id":"b1c9d466-a4a2-4f44-81a3-db2cd16322b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04236414","created_at":"2021-01-18T20:36:13.368Z","updated_at":"2025-02-25T17:00:24.608Z","phase":"Phase 1","brief_title":"Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours","source_id_and_acronym":"NCT04236414","lead_sponsor":"AstraZeneca","biomarkers":" HRD • BRCA","pipe":"","alterations":" ","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/14/2020","start_date":" 01/14/2020","primary_txt":" Primary completion: 02/14/2025","primary_completion_date":" 02/14/2025","study_txt":" Completion: 02/14/2025","study_completion_date":" 02/14/2025","last_update_posted":"2025-02-03"},{"id":"da831d56-b69a-4333-9086-5a3e811681fc","acronym":"AMPLITUDE","url":"https://clinicaltrials.gov/study/NCT04497844","created_at":"2021-01-18T21:32:59.167Z","updated_at":"2025-02-25T17:00:35.684Z","phase":"Phase 3","brief_title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","source_id_and_acronym":"NCT04497844 - AMPLITUDE","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HRD • BRCA","pipe":"","alterations":" ","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 696","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 01/07/2025","primary_completion_date":" 01/07/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-03"},{"id":"f228ffce-69d8-4696-a61e-6222a211f51d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188508","created_at":"2022-01-12T14:53:32.609Z","updated_at":"2025-02-25T16:17:09.399Z","phase":"Phase 2","brief_title":"Pembrolizumab, Olaparib, and Temozolomide for People with Glioma","source_id_and_acronym":"NCT05188508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type","tags":["EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"b72b0a64-54a8-4a42-8b82-b948a538ae47","acronym":"CAPRI","url":"https://clinicaltrials.gov/study/NCT03462342","created_at":"2021-01-18T17:04:00.829Z","updated_at":"2025-02-25T14:58:45.950Z","phase":"Phase 2","brief_title":"Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03462342 - CAPRI","lead_sponsor":"University of Pennsylvania","biomarkers":" HRD • BRCA • MUC16","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-31"},{"id":"27645473-7a93-4f67-8b27-cef657563cbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05021562","created_at":"2021-08-25T14:53:28.046Z","updated_at":"2025-02-25T17:30:52.775Z","phase":"","brief_title":"A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice","source_id_and_acronym":"NCT05021562","lead_sponsor":"Takeda","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 354","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-01-30"},{"id":"66e980f4-fc20-4c1f-b295-732ba31ba490","acronym":"","url":"https://clinicaltrials.gov/study/NCT02345265","created_at":"2021-01-18T11:09:11.903Z","updated_at":"2025-02-25T17:29:14.435Z","phase":"Phase 2","brief_title":"Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT02345265","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/23/2016","start_date":" 05/23/2016","primary_txt":" Primary completion: 07/07/2022","primary_completion_date":" 07/07/2022","study_txt":" Completion: 08/09/2025","study_completion_date":" 08/09/2025","last_update_posted":"2025-01-30"},{"id":"a170957e-b723-496d-b981-b2bbe36c4fc4","acronym":"EFFORT","url":"https://clinicaltrials.gov/study/NCT03579316","created_at":"2021-01-18T17:36:17.068Z","updated_at":"2025-02-25T17:29:43.272Z","phase":"Phase 2","brief_title":"Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03579316 - EFFORT","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/07/2018","start_date":" 12/07/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-30"},{"id":"b8e5058b-32bb-4610-b262-21974b89110e","acronym":"SL03-OHD-101","url":"https://clinicaltrials.gov/study/NCT04406623","created_at":"2021-01-18T21:14:44.896Z","updated_at":"2025-02-25T17:30:15.356Z","phase":"Phase 1","brief_title":"Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer","source_id_and_acronym":"NCT04406623 - SL03-OHD-101","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 02/02/2023","primary_completion_date":" 02/02/2023","study_txt":" Completion: 02/02/2023","study_completion_date":" 02/02/2023","last_update_posted":"2025-01-30"},{"id":"66081ec9-8bfe-411c-9d59-68a619e9fe86","acronym":"SCOUT-1","url":"https://clinicaltrials.gov/study/NCT04830709","created_at":"2021-04-05T13:53:00.171Z","updated_at":"2025-02-25T17:37:04.458Z","phase":"","brief_title":"Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer","source_id_and_acronym":"NCT04830709 - SCOUT-1","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 03/31/2033","study_completion_date":" 03/31/2033","last_update_posted":"2025-01-29"},{"id":"6b8fc966-3ab9-41b6-9e44-57638a4042ab","acronym":"DUO-O","url":"https://clinicaltrials.gov/study/NCT03737643","created_at":"2021-01-18T18:18:25.912Z","updated_at":"2025-02-25T17:36:10.253Z","phase":"Phase 3","brief_title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","source_id_and_acronym":"NCT03737643 - DUO-O","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2 • HRD","pipe":" | ","alterations":" HRD","tags":["BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1407","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 03/28/2025","primary_completion_date":" 03/28/2025","study_txt":" Completion: 03/30/2028","study_completion_date":" 03/30/2028","last_update_posted":"2025-01-29"},{"id":"48ebb4ce-018d-45cd-aa6d-684ba255450f","acronym":"L2-267","url":"https://clinicaltrials.gov/study/NCT06762379","created_at":"2025-02-26T07:26:34.478Z","updated_at":"2025-02-26T07:26:34.478Z","phase":"","brief_title":"Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration","source_id_and_acronym":"NCT06762379 - L2-267","lead_sponsor":"European Institute of Oncology","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 12/20/2024","start_date":" 12/20/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-01-07"},{"id":"171e76bb-7521-479f-b3fa-159564cab21b","acronym":"PROpelSub","url":"https://clinicaltrials.gov/study/NCT05171816","created_at":"2021-12-29T14:53:52.881Z","updated_at":"2025-02-25T16:17:05.784Z","phase":"Phase 3","brief_title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","source_id_and_acronym":"NCT05171816 - PROpelSub","lead_sponsor":"AstraZeneca","biomarkers":" HRD","pipe":" | ","alterations":" BRCA1 mutation","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • abiraterone acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 06/24/2021","start_date":" 06/24/2021","primary_txt":" Primary completion: 01/22/2024","primary_completion_date":" 01/22/2024","study_txt":" Completion: 04/28/2026","study_completion_date":" 04/28/2026","last_update_posted":"2025-01-03"},{"id":"04a57d4f-2959-452c-80a6-f0212d657b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04992013","created_at":"2021-08-05T13:53:09.751Z","updated_at":"2025-02-25T13:12:43.122Z","phase":"Phase 2","brief_title":"Niraparib in Tumors Metastatic to the CNS","source_id_and_acronym":"NCT04992013","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3","pipe":" | ","alterations":" HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/05/2022","start_date":" 04/05/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"b1021c14-5399-4865-b4e3-db5fb8024093","acronym":"LYNK-002","url":"https://clinicaltrials.gov/study/NCT03742895","created_at":"2021-01-18T18:19:59.379Z","updated_at":"2025-02-25T15:08:07.786Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","source_id_and_acronym":"NCT03742895 - LYNK-002","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" PGR positive • BRCA mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-12-09"}]